nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—lung cancer	0.221	1	CbGbCtD
Brimonidine—Clonidine—CYP1A1—lung cancer	0.00149	0.653	CrCbGaD
Brimonidine—Clonidine—ABCB1—lung cancer	0.000792	0.347	CrCbGaD
Brimonidine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000481	0.000741	CcSEcCtD
Brimonidine—Tachycardia—Cisplatin—lung cancer	0.000481	0.000739	CcSEcCtD
Brimonidine—Rash—Erlotinib—lung cancer	0.00048	0.000738	CcSEcCtD
Brimonidine—Dermatitis—Erlotinib—lung cancer	0.000479	0.000737	CcSEcCtD
Brimonidine—Palpitations—Paclitaxel—lung cancer	0.000479	0.000737	CcSEcCtD
Brimonidine—Angiopathy—Docetaxel—lung cancer	0.000479	0.000737	CcSEcCtD
Brimonidine—Skin disorder—Cisplatin—lung cancer	0.000478	0.000736	CcSEcCtD
Brimonidine—Insomnia—Gemcitabine—lung cancer	0.000478	0.000735	CcSEcCtD
Brimonidine—Dyspepsia—Irinotecan—lung cancer	0.000477	0.000735	CcSEcCtD
Brimonidine—Hypertension—Etoposide—lung cancer	0.000477	0.000734	CcSEcCtD
Brimonidine—Immune system disorder—Docetaxel—lung cancer	0.000477	0.000733	CcSEcCtD
Brimonidine—Headache—Erlotinib—lung cancer	0.000476	0.000733	CcSEcCtD
Brimonidine—Loss of consciousness—Paclitaxel—lung cancer	0.000476	0.000733	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—lung cancer	0.000476	0.000733	CcSEcCtD
Brimonidine—Mediastinal disorder—Docetaxel—lung cancer	0.000476	0.000732	CcSEcCtD
Brimonidine—Paraesthesia—Gemcitabine—lung cancer	0.000474	0.00073	CcSEcCtD
Brimonidine—Cough—Paclitaxel—lung cancer	0.000473	0.000728	CcSEcCtD
Brimonidine—Asthenia—Vinorelbine—lung cancer	0.000472	0.000726	CcSEcCtD
Brimonidine—Arrhythmia—Docetaxel—lung cancer	0.000471	0.000725	CcSEcCtD
Brimonidine—Dyspnoea—Gemcitabine—lung cancer	0.000471	0.000725	CcSEcCtD
Brimonidine—Chest pain—Etoposide—lung cancer	0.000471	0.000724	CcSEcCtD
Brimonidine—Nausea—Vinblastine—lung cancer	0.00047	0.000723	CcSEcCtD
Brimonidine—Somnolence—Gemcitabine—lung cancer	0.00047	0.000723	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000468	0.00072	CcSEcCtD
Brimonidine—Hypertension—Paclitaxel—lung cancer	0.000468	0.00072	CcSEcCtD
Brimonidine—Fatigue—Irinotecan—lung cancer	0.000468	0.000719	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000467	0.000719	CcSEcCtD
Brimonidine—Pruritus—Vinorelbine—lung cancer	0.000465	0.000716	CcSEcCtD
Brimonidine—Discomfort—Etoposide—lung cancer	0.000465	0.000715	CcSEcCtD
Brimonidine—Pain—Irinotecan—lung cancer	0.000464	0.000714	CcSEcCtD
Brimonidine—Mental disorder—Docetaxel—lung cancer	0.000462	0.000711	CcSEcCtD
Brimonidine—Arthralgia—Paclitaxel—lung cancer	0.000461	0.00071	CcSEcCtD
Brimonidine—Chest pain—Paclitaxel—lung cancer	0.000461	0.00071	CcSEcCtD
Brimonidine—Myalgia—Paclitaxel—lung cancer	0.000461	0.00071	CcSEcCtD
Brimonidine—Hypotension—Cisplatin—lung cancer	0.00046	0.000708	CcSEcCtD
Brimonidine—Anxiety—Paclitaxel—lung cancer	0.00046	0.000708	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—lung cancer	0.00046	0.000707	CcSEcCtD
Brimonidine—Erythema—Docetaxel—lung cancer	0.000459	0.000707	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000458	0.000705	CcSEcCtD
Brimonidine—Nausea—Topotecan—lung cancer	0.000457	0.000703	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000456	0.000702	CcSEcCtD
Brimonidine—Discomfort—Paclitaxel—lung cancer	0.000456	0.000701	CcSEcCtD
Brimonidine—Fatigue—Gemcitabine—lung cancer	0.000455	0.000701	CcSEcCtD
Brimonidine—Pain—Gemcitabine—lung cancer	0.000452	0.000695	CcSEcCtD
Brimonidine—Nausea—Erlotinib—lung cancer	0.000452	0.000695	CcSEcCtD
Brimonidine—Dry mouth—Paclitaxel—lung cancer	0.000451	0.000694	CcSEcCtD
Brimonidine—Dysgeusia—Docetaxel—lung cancer	0.00045	0.000692	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000449	0.00069	CcSEcCtD
Brimonidine—Infection—Etoposide—lung cancer	0.000448	0.00069	CcSEcCtD
Brimonidine—Oedema—Paclitaxel—lung cancer	0.000442	0.000681	CcSEcCtD
Brimonidine—Paraesthesia—Cisplatin—lung cancer	0.000442	0.00068	CcSEcCtD
Brimonidine—Tachycardia—Etoposide—lung cancer	0.00044	0.000677	CcSEcCtD
Brimonidine—Infection—Paclitaxel—lung cancer	0.000439	0.000676	CcSEcCtD
Brimonidine—Dyspnoea—Cisplatin—lung cancer	0.000439	0.000676	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—lung cancer	0.000438	0.000674	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—lung cancer	0.000436	0.000671	CcSEcCtD
Brimonidine—Shock—Paclitaxel—lung cancer	0.000435	0.00067	CcSEcCtD
Brimonidine—Dizziness—Vinorelbine—lung cancer	0.000435	0.000669	CcSEcCtD
Brimonidine—Nervous system disorder—Paclitaxel—lung cancer	0.000434	0.000667	CcSEcCtD
Brimonidine—Tachycardia—Paclitaxel—lung cancer	0.000432	0.000664	CcSEcCtD
Brimonidine—Skin disorder—Paclitaxel—lung cancer	0.00043	0.000661	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—lung cancer	0.000426	0.000655	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000425	0.000654	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—lung cancer	0.000424	0.000652	CcSEcCtD
Brimonidine—Depression—Methotrexate—lung cancer	0.000422	0.00065	CcSEcCtD
Brimonidine—Hypotension—Etoposide—lung cancer	0.000422	0.000649	CcSEcCtD
Brimonidine—Pain—Cisplatin—lung cancer	0.000421	0.000648	CcSEcCtD
Brimonidine—Rash—Vinorelbine—lung cancer	0.000415	0.000638	CcSEcCtD
Brimonidine—Dermatitis—Vinorelbine—lung cancer	0.000414	0.000637	CcSEcCtD
Brimonidine—Hypotension—Paclitaxel—lung cancer	0.000413	0.000636	CcSEcCtD
Brimonidine—Headache—Vinorelbine—lung cancer	0.000412	0.000634	CcSEcCtD
Brimonidine—Syncope—Docetaxel—lung cancer	0.000412	0.000634	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—lung cancer	0.000412	0.000634	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—lung cancer	0.000411	0.000633	CcSEcCtD
Brimonidine—Palpitations—Docetaxel—lung cancer	0.000406	0.000625	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—lung cancer	0.000405	0.000623	CcSEcCtD
Brimonidine—Loss of consciousness—Docetaxel—lung cancer	0.000404	0.000621	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000403	0.00062	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—lung cancer	0.000402	0.000619	CcSEcCtD
Brimonidine—Somnolence—Etoposide—lung cancer	0.000401	0.000617	CcSEcCtD
Brimonidine—Cough—Docetaxel—lung cancer	0.000401	0.000617	CcSEcCtD
Brimonidine—Insomnia—Paclitaxel—lung cancer	0.0004	0.000616	CcSEcCtD
Brimonidine—Hypersensitivity—Irinotecan—lung cancer	0.0004	0.000615	CcSEcCtD
Brimonidine—Paraesthesia—Paclitaxel—lung cancer	0.000397	0.000611	CcSEcCtD
Brimonidine—Hypertension—Docetaxel—lung cancer	0.000397	0.00061	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—lung cancer	0.000396	0.000609	CcSEcCtD
Brimonidine—Dyspnoea—Paclitaxel—lung cancer	0.000394	0.000607	CcSEcCtD
Brimonidine—Somnolence—Paclitaxel—lung cancer	0.000393	0.000605	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—lung cancer	0.000391	0.000602	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—lung cancer	0.000391	0.000602	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—lung cancer	0.000391	0.000602	CcSEcCtD
Brimonidine—Nausea—Vinorelbine—lung cancer	0.000391	0.000601	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—lung cancer	0.000389	0.000599	CcSEcCtD
Brimonidine—Dyspepsia—Paclitaxel—lung cancer	0.000389	0.000599	CcSEcCtD
Brimonidine—Asthenia—Irinotecan—lung cancer	0.000389	0.000599	CcSEcCtD
Brimonidine—Fatigue—Etoposide—lung cancer	0.000389	0.000598	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000388	0.000598	CcSEcCtD
Brimonidine—Pain—Etoposide—lung cancer	0.000386	0.000594	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—lung cancer	0.000382	0.000589	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000382	0.000588	CcSEcCtD
Brimonidine—Fatigue—Paclitaxel—lung cancer	0.000381	0.000587	CcSEcCtD
Brimonidine—Asthenia—Gemcitabine—lung cancer	0.000379	0.000583	CcSEcCtD
Brimonidine—Pain—Paclitaxel—lung cancer	0.000378	0.000582	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—lung cancer	0.000377	0.000581	CcSEcCtD
Brimonidine—Oedema—Docetaxel—lung cancer	0.000375	0.000577	CcSEcCtD
Brimonidine—Pruritus—Gemcitabine—lung cancer	0.000374	0.000575	CcSEcCtD
Brimonidine—Infection—Docetaxel—lung cancer	0.000372	0.000573	CcSEcCtD
Brimonidine—Shock—Docetaxel—lung cancer	0.000369	0.000568	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—lung cancer	0.000368	0.000566	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—lung cancer	0.000367	0.000565	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—lung cancer	0.000367	0.000564	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—lung cancer	0.000366	0.000563	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—lung cancer	0.000364	0.00056	CcSEcCtD
Brimonidine—Hypersensitivity—Cisplatin—lung cancer	0.000363	0.000558	CcSEcCtD
Brimonidine—Dizziness—Irinotecan—lung cancer	0.000359	0.000552	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—lung cancer	0.000357	0.000549	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—lung cancer	0.000355	0.000547	CcSEcCtD
Brimonidine—Asthenia—Cisplatin—lung cancer	0.000353	0.000544	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—lung cancer	0.000353	0.000543	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—lung cancer	0.00035	0.000539	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—lung cancer	0.000345	0.000531	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—lung cancer	0.000344	0.00053	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—lung cancer	0.000344	0.000529	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—lung cancer	0.000343	0.000527	CcSEcCtD
Brimonidine—Rash—Irinotecan—lung cancer	0.000342	0.000526	CcSEcCtD
Brimonidine—Dermatitis—Irinotecan—lung cancer	0.000342	0.000526	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000342	0.000526	CcSEcCtD
Brimonidine—Headache—Irinotecan—lung cancer	0.00034	0.000523	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—lung cancer	0.000339	0.000522	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—lung cancer	0.000337	0.000518	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—lung cancer	0.000335	0.000516	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—lung cancer	0.000334	0.000514	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—lung cancer	0.000333	0.000513	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—lung cancer	0.000333	0.000513	CcSEcCtD
Brimonidine—Rash—Gemcitabine—lung cancer	0.000333	0.000513	CcSEcCtD
Brimonidine—Dermatitis—Gemcitabine—lung cancer	0.000333	0.000512	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—lung cancer	0.000332	0.000511	CcSEcCtD
Brimonidine—Erythema—Methotrexate—lung cancer	0.000331	0.000509	CcSEcCtD
Brimonidine—Headache—Gemcitabine—lung cancer	0.000331	0.000509	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—lung cancer	0.00033	0.000508	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—lung cancer	0.00033	0.000508	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—lung cancer	0.000327	0.000503	CcSEcCtD
Brimonidine—Hypersensitivity—Paclitaxel—lung cancer	0.000326	0.000501	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—lung cancer	0.000324	0.000499	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000324	0.000498	CcSEcCtD
Brimonidine—Asthenia—Etoposide—lung cancer	0.000324	0.000498	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—lung cancer	0.000323	0.000497	CcSEcCtD
Brimonidine—Nausea—Irinotecan—lung cancer	0.000322	0.000496	CcSEcCtD
Brimonidine—Pain—Docetaxel—lung cancer	0.000321	0.000493	CcSEcCtD
Brimonidine—Pruritus—Etoposide—lung cancer	0.000319	0.000491	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—lung cancer	0.000317	0.000488	CcSEcCtD
Brimonidine—Asthenia—Paclitaxel—lung cancer	0.000317	0.000488	CcSEcCtD
Brimonidine—Nausea—Gemcitabine—lung cancer	0.000314	0.000483	CcSEcCtD
Brimonidine—Pruritus—Paclitaxel—lung cancer	0.000313	0.000482	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—lung cancer	0.000312	0.00048	CcSEcCtD
Brimonidine—Rash—Cisplatin—lung cancer	0.00031	0.000478	CcSEcCtD
Brimonidine—Dermatitis—Cisplatin—lung cancer	0.00031	0.000477	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—lung cancer	0.000308	0.000474	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—lung cancer	0.000306	0.00047	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—lung cancer	0.000306	0.00047	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—lung cancer	0.000299	0.00046	CcSEcCtD
Brimonidine—Dizziness—Etoposide—lung cancer	0.000298	0.000459	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—lung cancer	0.000297	0.000458	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—lung cancer	0.000297	0.000457	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—lung cancer	0.000294	0.000453	CcSEcCtD
Brimonidine—Dizziness—Paclitaxel—lung cancer	0.000292	0.00045	CcSEcCtD
Brimonidine—Nausea—Cisplatin—lung cancer	0.000292	0.00045	CcSEcCtD
Brimonidine—Cough—Methotrexate—lung cancer	0.000289	0.000445	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—lung cancer	0.000289	0.000444	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—lung cancer	0.000287	0.000441	CcSEcCtD
Brimonidine—Rash—Etoposide—lung cancer	0.000284	0.000438	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—lung cancer	0.000284	0.000437	CcSEcCtD
Brimonidine—Headache—Etoposide—lung cancer	0.000283	0.000435	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—lung cancer	0.000282	0.000434	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—lung cancer	0.000282	0.000434	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—lung cancer	0.000282	0.000434	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—lung cancer	0.000281	0.000432	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.00028	0.000431	CcSEcCtD
Brimonidine—Rash—Paclitaxel—lung cancer	0.000279	0.000429	CcSEcCtD
Brimonidine—Dermatitis—Paclitaxel—lung cancer	0.000279	0.000429	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—lung cancer	0.000278	0.000429	CcSEcCtD
Brimonidine—Headache—Paclitaxel—lung cancer	0.000277	0.000426	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—lung cancer	0.000276	0.000425	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—lung cancer	0.00027	0.000416	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—lung cancer	0.000269	0.000414	CcSEcCtD
Brimonidine—Infection—Methotrexate—lung cancer	0.000268	0.000413	CcSEcCtD
Brimonidine—Nausea—Etoposide—lung cancer	0.000268	0.000412	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—lung cancer	0.000265	0.000408	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—lung cancer	0.000265	0.000408	CcSEcCtD
Brimonidine—Nausea—Paclitaxel—lung cancer	0.000263	0.000404	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—lung cancer	0.000262	0.000404	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—lung cancer	0.000257	0.000396	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—lung cancer	0.000253	0.00039	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—lung cancer	0.000252	0.000389	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—lung cancer	0.000252	0.000388	CcSEcCtD
Brimonidine—Cough—Doxorubicin—lung cancer	0.00025	0.000385	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—lung cancer	0.000248	0.000381	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—lung cancer	0.000248	0.000381	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000246	0.000379	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—lung cancer	0.000244	0.000376	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—lung cancer	0.000244	0.000376	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—lung cancer	0.000244	0.000376	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—lung cancer	0.000244	0.000376	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—lung cancer	0.000243	0.000374	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—lung cancer	0.000243	0.000373	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000242	0.000373	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—lung cancer	0.000241	0.000371	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—lung cancer	0.000241	0.000371	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—lung cancer	0.00024	0.00037	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—lung cancer	0.000239	0.000367	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—lung cancer	0.000238	0.000366	CcSEcCtD
Brimonidine—Rash—Docetaxel—lung cancer	0.000236	0.000364	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—lung cancer	0.000236	0.000363	CcSEcCtD
Brimonidine—Headache—Docetaxel—lung cancer	0.000235	0.000361	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—lung cancer	0.000234	0.00036	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000233	0.000359	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—lung cancer	0.000233	0.000358	CcSEcCtD
Brimonidine—Infection—Doxorubicin—lung cancer	0.000232	0.000358	CcSEcCtD
Brimonidine—Pain—Methotrexate—lung cancer	0.000231	0.000356	CcSEcCtD
Brimonidine—Shock—Doxorubicin—lung cancer	0.00023	0.000354	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—lung cancer	0.000229	0.000353	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—lung cancer	0.000228	0.000351	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—lung cancer	0.000227	0.00035	CcSEcCtD
Brimonidine—Nausea—Docetaxel—lung cancer	0.000223	0.000343	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—lung cancer	0.000219	0.000336	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000213	0.000328	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—lung cancer	0.000212	0.000326	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—lung cancer	0.00021	0.000323	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—lung cancer	0.000209	0.000321	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—lung cancer	0.000208	0.00032	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—lung cancer	0.000206	0.000317	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000202	0.000311	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—lung cancer	0.000202	0.00031	CcSEcCtD
Brimonidine—Pain—Doxorubicin—lung cancer	0.0002	0.000308	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—lung cancer	0.000199	0.000306	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—lung cancer	0.000194	0.000298	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—lung cancer	0.000191	0.000294	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—lung cancer	0.000179	0.000275	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—lung cancer	0.000172	0.000265	CcSEcCtD
Brimonidine—Rash—Methotrexate—lung cancer	0.00017	0.000262	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—lung cancer	0.00017	0.000262	CcSEcCtD
Brimonidine—Headache—Methotrexate—lung cancer	0.000169	0.00026	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—lung cancer	0.000168	0.000258	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—lung cancer	0.000166	0.000255	CcSEcCtD
Brimonidine—Nausea—Methotrexate—lung cancer	0.000161	0.000247	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—lung cancer	0.000155	0.000238	CcSEcCtD
Brimonidine—Rash—Doxorubicin—lung cancer	0.000148	0.000227	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—lung cancer	0.000147	0.000227	CcSEcCtD
Brimonidine—Headache—Doxorubicin—lung cancer	0.000147	0.000226	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—lung cancer	0.000139	0.000214	CcSEcCtD
Brimonidine—ADRA2B—Signaling Pathways—IGF1R—lung cancer	4e-05	0.000317	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PIK3CA—lung cancer	4e-05	0.000316	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—SRC—lung cancer	3.99e-05	0.000316	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCL8—lung cancer	3.98e-05	0.000315	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HES1—lung cancer	3.93e-05	0.000311	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—POMC—lung cancer	3.91e-05	0.000309	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—lung cancer	3.88e-05	0.000307	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AVP—lung cancer	3.88e-05	0.000307	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CB—lung cancer	3.87e-05	0.000306	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—lung cancer	3.87e-05	0.000306	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTP1—lung cancer	3.86e-05	0.000305	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—RAF1—lung cancer	3.86e-05	0.000305	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JUNB—lung cancer	3.84e-05	0.000304	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NRAS—lung cancer	3.84e-05	0.000304	CbGpPWpGaD
Brimonidine—AOX1—Disease—HRAS—lung cancer	3.84e-05	0.000304	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—lung cancer	3.81e-05	0.000301	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CB—lung cancer	3.76e-05	0.000298	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CAT—lung cancer	3.76e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1R—lung cancer	3.74e-05	0.000296	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—lung cancer	3.74e-05	0.000296	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—lung cancer	3.73e-05	0.000295	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL8—lung cancer	3.72e-05	0.000295	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HRAS—lung cancer	3.7e-05	0.000293	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—MAPK3—lung cancer	3.67e-05	0.000291	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HES1—lung cancer	3.67e-05	0.000291	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—lung cancer	3.67e-05	0.000291	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ABCB1—lung cancer	3.65e-05	0.000289	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL8—lung cancer	3.62e-05	0.000286	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—lung cancer	3.61e-05	0.000286	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CD—lung cancer	3.61e-05	0.000286	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—RAF1—lung cancer	3.6e-05	0.000285	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB3—lung cancer	3.59e-05	0.000284	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TYMS—lung cancer	3.59e-05	0.000284	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—lung cancer	3.56e-05	0.000281	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOA1—lung cancer	3.55e-05	0.000281	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—POMC—lung cancer	3.55e-05	0.000281	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTM1—lung cancer	3.55e-05	0.000281	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—lung cancer	3.52e-05	0.000278	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STK11—lung cancer	3.49e-05	0.000276	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—lung cancer	3.47e-05	0.000275	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6R—lung cancer	3.46e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—lung cancer	3.46e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—lung cancer	3.46e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—lung cancer	3.44e-05	0.000273	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—lung cancer	3.39e-05	0.000268	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL8—lung cancer	3.38e-05	0.000267	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO3—lung cancer	3.37e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1A1—lung cancer	3.36e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB3—lung cancer	3.36e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGFR1—lung cancer	3.34e-05	0.000265	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ERCC2—lung cancer	3.33e-05	0.000264	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—lung cancer	3.3e-05	0.000261	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAP2K1—lung cancer	3.3e-05	0.000261	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—lung cancer	3.29e-05	0.000261	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—lung cancer	3.28e-05	0.000259	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—lung cancer	3.27e-05	0.000259	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—lung cancer	3.24e-05	0.000257	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—lung cancer	3.23e-05	0.000256	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—lung cancer	3.22e-05	0.000255	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOA1—lung cancer	3.18e-05	0.000252	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AVP—lung cancer	3.15e-05	0.00025	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—lung cancer	3.15e-05	0.000249	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—lung cancer	3.15e-05	0.000249	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGFR1—lung cancer	3.12e-05	0.000247	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—POMC—lung cancer	3.09e-05	0.000244	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—lung cancer	3.08e-05	0.000244	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—lung cancer	3.05e-05	0.000242	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1R—lung cancer	3.04e-05	0.00024	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—lung cancer	3.03e-05	0.00024	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL8—lung cancer	3.02e-05	0.000239	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CREBBP—lung cancer	3.01e-05	0.000238	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES1—lung cancer	2.98e-05	0.000236	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOA1—lung cancer	2.97e-05	0.000235	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—lung cancer	2.94e-05	0.000233	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—lung cancer	2.94e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—RAF1—lung cancer	2.93e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—lung cancer	2.9e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—lung cancer	2.9e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APC—lung cancer	2.9e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—lung cancer	2.9e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—lung cancer	2.89e-05	0.000229	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOA1—lung cancer	2.88e-05	0.000228	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGF—lung cancer	2.87e-05	0.000227	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—lung cancer	2.86e-05	0.000226	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—lung cancer	2.85e-05	0.000226	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—lung cancer	2.84e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—lung cancer	2.81e-05	0.000223	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—lung cancer	2.81e-05	0.000222	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK3—lung cancer	2.78e-05	0.00022	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—POMC—lung cancer	2.76e-05	0.000219	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL8—lung cancer	2.74e-05	0.000217	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BRAF—lung cancer	2.73e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB3—lung cancer	2.73e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—lung cancer	2.71e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—lung cancer	2.71e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APC—lung cancer	2.71e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—lung cancer	2.71e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6R—lung cancer	2.69e-05	0.000213	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREBBP—lung cancer	2.69e-05	0.000213	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGF—lung cancer	2.68e-05	0.000212	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—lung cancer	2.64e-05	0.000209	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—lung cancer	2.63e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—lung cancer	2.62e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—lung cancer	2.61e-05	0.000207	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK3—lung cancer	2.6e-05	0.000205	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—POMC—lung cancer	2.58e-05	0.000204	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAP2K1—lung cancer	2.57e-05	0.000203	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—lung cancer	2.55e-05	0.000202	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BRAF—lung cancer	2.55e-05	0.000202	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	2.54e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—lung cancer	2.53e-05	0.0002	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6R—lung cancer	2.52e-05	0.000199	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREBBP—lung cancer	2.51e-05	0.000199	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—POMC—lung cancer	2.51e-05	0.000198	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	2.5e-05	0.000198	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—lung cancer	2.5e-05	0.000198	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—lung cancer	2.48e-05	0.000197	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—lung cancer	2.48e-05	0.000196	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—lung cancer	2.47e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—lung cancer	2.46e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CREBBP—lung cancer	2.44e-05	0.000193	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOA1—lung cancer	2.41e-05	0.000191	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAP2K1—lung cancer	2.4e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—lung cancer	2.39e-05	0.000189	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	2.38e-05	0.000189	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	2.36e-05	0.000187	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—lung cancer	2.33e-05	0.000185	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—lung cancer	2.32e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	2.29e-05	0.000182	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—lung cancer	2.29e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—lung cancer	2.29e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAF1—lung cancer	2.28e-05	0.00018	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—lung cancer	2.25e-05	0.000178	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MTOR—lung cancer	2.22e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	2.22e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	2.2e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—lung cancer	2.2e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APC—lung cancer	2.2e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	2.2e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGF—lung cancer	2.18e-05	0.000172	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—lung cancer	2.15e-05	0.00017	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	2.14e-05	0.00017	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL8—lung cancer	2.14e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—lung cancer	2.14e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAF1—lung cancer	2.13e-05	0.000168	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—lung cancer	2.12e-05	0.000168	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	2.11e-05	0.000167	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—lung cancer	2.11e-05	0.000167	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—POMC—lung cancer	2.1e-05	0.000166	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MTOR—lung cancer	2.08e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	2.08e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BRAF—lung cancer	2.07e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	2.06e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—EP300—lung cancer	2.05e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—lung cancer	2.05e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6R—lung cancer	2.04e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—lung cancer	2.04e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	2.04e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—lung cancer	2.03e-05	0.000161	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—lung cancer	2.02e-05	0.00016	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	2.01e-05	0.000159	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—lung cancer	2e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL8—lung cancer	2e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—lung cancer	1.99e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JUN—lung cancer	1.99e-05	0.000157	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—lung cancer	1.98e-05	0.000157	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	1.95e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	1.94e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—lung cancer	1.93e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	1.93e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	1.93e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—lung cancer	1.92e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.92e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—lung cancer	1.91e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—lung cancer	1.91e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—lung cancer	1.9e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	1.9e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	1.87e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.86e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JUN—lung cancer	1.86e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EP300—lung cancer	1.83e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.81e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.8e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.8e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—lung cancer	1.78e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.75e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—lung cancer	1.74e-05	0.000138	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.74e-05	0.000138	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.74e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.73e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.73e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.72e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.71e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EP300—lung cancer	1.71e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.71e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.69e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.69e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—lung cancer	1.66e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—EP300—lung cancer	1.66e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.64e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.62e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.62e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.61e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.61e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.6e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—lung cancer	1.6e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.57e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.56e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.55e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—lung cancer	1.55e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.54e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.53e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—lung cancer	1.51e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.51e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JUN—lung cancer	1.51e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—lung cancer	1.49e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.48e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.47e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.46e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.46e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.46e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.42e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EP300—lung cancer	1.39e-05	0.00011	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—lung cancer	1.38e-05	0.000109	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.36e-05	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—lung cancer	1.35e-05	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.32e-05	0.000104	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—lung cancer	1.31e-05	0.000104	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.3e-05	0.000103	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.3e-05	0.000103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	1.27e-05	0.0001	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.25e-05	9.93e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.25e-05	9.86e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—lung cancer	1.24e-05	9.79e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—lung cancer	1.23e-05	9.74e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—lung cancer	1.23e-05	9.7e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—lung cancer	1.21e-05	9.59e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—lung cancer	1.2e-05	9.5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.19e-05	9.38e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—lung cancer	1.17e-05	9.27e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—lung cancer	1.12e-05	8.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.12e-05	8.86e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.11e-05	8.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—lung cancer	1.03e-05	8.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.03e-05	8.14e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—lung cancer	1e-05	7.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—lung cancer	9.95e-06	7.88e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—lung cancer	9.52e-06	7.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—lung cancer	9.11e-06	7.21e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—lung cancer	8.4e-06	6.65e-05	CbGpPWpGaD
